October 2021

VPCIR biosciences launches a webshop offering its first commercial product: A human topoisomerase 1 (hTOP1) enzyme for laboratory use available now

July 2021

VPCIR biosciences have obtained European trademark protection for our disruptive VPCIR technology. We expect to launch the first VPCIR™ products in about 6 months time

March 2021

VPCIR has successfully negotiated a €134.000 loan arrangement with the Danish Vaekstfonden

December 2020

The group of dedicated business angels, organized in VPCIR Invest ApS decides to increase their commitment and investment level in VPCIR

May 2020

EU Commission grants Seal of Excellence to VPCIR biosciences Aps

December 2019

Investment by a group of Danish business angels at DKK 1.7 M

December 2018

VPCIR receives a grant of DKK 0.9M from Novo Nordisk Foundation

November 2018

Development of first-generation assay (Listeria) commences

October 2018

VPCIR receives a grant of DKK 1.5M from Innovation Fund Denmark

April 2018

Submission of VPCIR patent application by AU/CUHK

February 2018

Establishment of VPCIR biosciences ApS

September 2017

Proof of concept in testing for E. coli using restriction enzyme patterns

2010 - 2017

Basic research Aarhus University (AU), Aarhus University Hospital and Chinese University of Hong Kong (CUHK) on restriction enzymes